James E Fickenscher insider trades: Zynerba Pharmaceuticals (ZYNE) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where James reports to the SEC
Open-market buys and sales
23 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 13, 2023 | ZYNE | ↓ Sell | 8,998 | $1.33 | $12K | Direct | Sep 14, 2023 (1d) |
| Jan 23, 2023 | ZYNE | ↓ Sell | 17,769 | $0.60 | $11K | Direct | Jan 25, 2023 (2d) |
| Jul 19, 2022 | ZYNE | ↓ Sell | 6,013 | $1.10 | $7K | Direct | Jul 20, 2022 (1d) |
| Aug 6, 2018 | ZYNE | ↑ Buy | 8,518 | $5.97 | $51K | Direct | Aug 7, 2018 (1d) |
| May 12, 2017 | ZYNE | ↑ Buy | 5,200 | $19.82 | $103K | Direct | May 16, 2017 (4d) |
| Dec 7, 2016 | ZYNE | ↑ Buy | 7,000 | $14.08 | $99K | Direct | Dec 8, 2016 (1d) |
| Mar 18, 2016 | ATRS | ↑ Buy | 135,000 | $0.72 | $97K | Direct | Mar 21, 2016 (3d) |
| Dec 11, 2014 | ATRS | ↑ Buy | 40,000 | $2.50 | $100K | Direct | Dec 15, 2014 (4d) |
| Dec 11, 2013 | AUXL | ↓ Sell10b5-1 | 71,067 | $20.37 | $1.4M | Direct | Dec 12, 2013 (1d) |
| Nov 3, 2011 | AUXL | ↑ Buy | 1,610 | $15.54 | $25K | Direct | Nov 7, 2011 (4d) |
| Sep 14, 2009 | AUXL | ↓ Sell | 4,000 | $30.70 | $123K | Direct | Sep 16, 2009 (2d) |
| Sep 8, 2009 | AUXL | ↓ Sell | 4,000 | $30.00 | $120K | Direct | Sep 10, 2009 (2d) |
| Jul 15, 2009 | AUXL | ↓ Sell | 4,000 | $30.01 | $120K | Direct | Jul 17, 2009 (2d) |
| Jun 15, 2009 | AUXL | ↓ Sell | 4,000 | $27.21 | $109K | Direct | Jun 17, 2009 (2d) |
| May 22, 2009 | AUXL | ↓ Sell | 4,000 | $25.02 | $100K | Direct | May 27, 2009 (5d) |
| Apr 17, 2009 | AUXL | ↓ Sell | 4,000 | $25.01 | $100K | Direct | Apr 20, 2009 (3d) |
| Mar 16, 2009 | AUXL | ↓ Sell | 4,933 | $29.79 | $147K | Direct | Mar 17, 2009 (1d) |
| Feb 17, 2009 | AUXL | ↓ Sell | 3,450 | $31.55 | $109K | Direct | Feb 19, 2009 (2d) |
| Jan 14, 2009 | AUXL | ↓ Sell | 3,942 | $29.04 | $114K | Direct | Jan 16, 2009 (2d) |
| Dec 19, 2008 | AUXL | ↓ Sell | 11,675 | $26.31 | $307K | Direct | Dec 22, 2008 (3d) |
| May 8, 2007 | AUXL | ↑ Buy | 1,510 | $13.38 | $20K | Direct | May 10, 2007 (2d) |
| Mar 10, 2006 | AUXL | ↑ Buy | 1,000 | $6.43 | $6K | Direct | Mar 14, 2006 (4d) |
| Nov 11, 2005 | AUXL | ↑ Buy | 5,000 | $4.24 | $21K | Direct | Nov 14, 2005 (3d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About James E Fickenscher's insider trades
James E Fickenscher is Chief Financial Officer at Zynerba Pharmaceuticals (ZYNE). Since Nov 11, 2005, James has reported 9 open-market purchases worth $522K and 14 sales worth $2.8M on SEC Form 4. There have been no open-market trades in the last 12 months.
1 sale (51% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.
Their filings also include grants and awards (31 filings), shares withheld for taxes (13 filings), option exercises (8 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ZYNE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.